JP2022531141A5 - - Google Patents

Info

Publication number
JP2022531141A5
JP2022531141A5 JP2021563181A JP2021563181A JP2022531141A5 JP 2022531141 A5 JP2022531141 A5 JP 2022531141A5 JP 2021563181 A JP2021563181 A JP 2021563181A JP 2021563181 A JP2021563181 A JP 2021563181A JP 2022531141 A5 JP2022531141 A5 JP 2022531141A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
sequence described
domain containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021563181A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022531141A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/029934 external-priority patent/WO2020219964A1/en
Publication of JP2022531141A publication Critical patent/JP2022531141A/ja
Publication of JP2022531141A5 publication Critical patent/JP2022531141A5/ja
Priority to JP2025093134A priority Critical patent/JP2025131704A/ja
Pending legal-status Critical Current

Links

JP2021563181A 2019-04-24 2020-04-24 遺伝子治療のコンディショニング方法 Pending JP2022531141A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025093134A JP2025131704A (ja) 2019-04-24 2025-06-04 遺伝子治療のためのコンディショニング方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962838278P 2019-04-24 2019-04-24
US62/838,278 2019-04-24
US201962944925P 2019-12-06 2019-12-06
US62/944,925 2019-12-06
PCT/US2020/029934 WO2020219964A1 (en) 2019-04-24 2020-04-24 Conditioning methods for gene therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025093134A Division JP2025131704A (ja) 2019-04-24 2025-06-04 遺伝子治療のためのコンディショニング方法

Publications (2)

Publication Number Publication Date
JP2022531141A JP2022531141A (ja) 2022-07-06
JP2022531141A5 true JP2022531141A5 (cg-RX-API-DMAC7.html) 2023-05-02

Family

ID=72940803

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021563181A Pending JP2022531141A (ja) 2019-04-24 2020-04-24 遺伝子治療のコンディショニング方法
JP2025093134A Pending JP2025131704A (ja) 2019-04-24 2025-06-04 遺伝子治療のためのコンディショニング方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025093134A Pending JP2025131704A (ja) 2019-04-24 2025-06-04 遺伝子治療のためのコンディショニング方法

Country Status (7)

Country Link
US (1) US20220175946A1 (cg-RX-API-DMAC7.html)
EP (1) EP3958878A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022531141A (cg-RX-API-DMAC7.html)
CN (1) CN113993550A (cg-RX-API-DMAC7.html)
AU (1) AU2020261079A1 (cg-RX-API-DMAC7.html)
CA (1) CA3134689A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020219964A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10882915B2 (en) 2017-10-24 2021-01-05 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD117+ cells
WO2019217942A1 (en) 2018-05-11 2019-11-14 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
CN113330026A (zh) * 2018-10-23 2021-08-31 美真达治疗公司 Fc沉默的抗体药物缀合物(ADC)及其用途
EP4543469A4 (en) * 2022-06-27 2026-06-03 Beam Therapeutics Inc COMPOSITIONS AND CONDITIONING METHODS OF NON-GENOTOXIC CELLS
WO2024073751A1 (en) * 2022-09-29 2024-04-04 Vor Biopharma Inc. Methods and compositions for gene modification and enrichment
IL322368A (en) * 2023-02-03 2025-09-01 Genzyme Corp HSC-specific antibody-conjugated lipid nanoparticles and their uses

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10111966B2 (en) * 2016-06-17 2018-10-30 Magenta Therapeutics, Inc. Methods for the depletion of CD117+ cells
CN109641051A (zh) * 2016-06-17 2019-04-16 美真达治疗公司 用于耗尽细胞的组合物和方法
US12485186B2 (en) * 2017-03-31 2025-12-02 The Children's Medical Center Corporation Antibody-mediated conditioning with immunosuppression to enable allogeneic transplantation
CA3070242A1 (en) * 2017-07-18 2019-01-24 Calimmune, Inc. Compositions and methods for treating beta-hemoglobinopathies
EP3700568A4 (en) * 2017-10-24 2021-11-10 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
US10882915B2 (en) * 2017-10-24 2021-01-05 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD117+ cells
US10924796B2 (en) * 2018-04-10 2021-02-16 Logitech Europe S.A. System and methods for interactive filters in live streaming media
CN113330026A (zh) * 2018-10-23 2021-08-31 美真达治疗公司 Fc沉默的抗体药物缀合物(ADC)及其用途
WO2020219778A2 (en) * 2019-04-24 2020-10-29 Magenta Therapeutics, Inc. Anti-cd117 antibody-drug conjugates and uses thereof
JP2022530438A (ja) * 2019-04-24 2022-06-29 マジェンタ セラピューティクス インコーポレイテッド 抗cd117抗体薬物複合体およびその使用
US20240115615A1 (en) * 2021-02-09 2024-04-11 Jasper Therapeutics, Inc. Modified stem cell compositions and methods for use
EP4419114A4 (en) * 2021-10-18 2025-10-15 Jasper Therapeutics Inc MODIFIED STEM CELL COMPOSITIONS AND METHODS OF USE THEREOF

Similar Documents

Publication Publication Date Title
JP2023520636A5 (cg-RX-API-DMAC7.html)
JP2021500391A5 (cg-RX-API-DMAC7.html)
JP2025160215A5 (cg-RX-API-DMAC7.html)
JP2019522050A5 (cg-RX-API-DMAC7.html)
WO2019084064A4 (en) Compositions and methods for the depletion of cd117+ cells
JP2022512629A5 (cg-RX-API-DMAC7.html)
KR0135632B1 (ko) 감염성 및 염증성 병변 표적용 항-백혈구 결합체 및 이를 함유하는 제제 및 키트
Krasniqi et al. Theranostic radiolabeled anti-CD20 sdAb for targeted radionuclide therapy of non-Hodgkin lymphoma
Le Doussal et al. Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy and immune response
JP5843884B2 (ja) 抗cd38抗体
US12371506B2 (en) Subcutaneous administration of anti-CD38 antibodies
EP4010082B2 (en) MULTISPECIFIC TCR DELTA VARIABLE DOMAIN 1 ANTIBODIES
JP2022553839A5 (cg-RX-API-DMAC7.html)
WO2019108863A4 (en) Compositions and methods for the depletion of cd5+ cells
WO2021188590A2 (en) T-cell bispecific binding proteins
SG11202110287QA (en) Amatoxin antibody-drug conjugates and uses thereof
MX2012009352A (es) "anticuerpos cd20 y su utilización".
US20240075157A1 (en) Fc silenced antibody drug conjugates (adcs) and uses thereof
US20260102505A1 (en) Anti-cd45-ign antibody drug conjugates and uses thereof
MY108519A (en) Novel antibodies reactive with human carcinomas.
JP4912153B2 (ja) タンパク質とキレート剤とのコンジュゲートを調製するための改良された方法
JP2024519970A (ja) 三価放射性同位体生物標的放射性医薬品、調製方法及び使用
WO2019108860A4 (en) Compositions and methods for the depletion of cd2+ cells
US20220177577A1 (en) Anti-cd117 antibody drug conjugates and uses thereof
US20220175946A1 (en) Conditioning methods for gene therapy